You are viewing an expired study

Boston, Massachusetts 02115

  • Cancer


This protocol is designed to obtain detailed information on the impact of body composition on the pharmacokinetic behavior of doxorubicin after a single intravenous dose in children 21 years of age or younger. There is no efficacy component. Approximately 9 children will be enrolled at Children's Hospital Boston. The information gained from this study could be very important in developing dosing strategies for doxorubicin in the obese patient population.


Inclusion Criteria: - Eligible patients will be > 1 and ≤ 21 years old. - All patients must be receiving chemotherapy that includes doxorubicin administered as an infusion of any duration < 24 hours, on either a 1-day or 2-day schedule. This includes bolus and all short infusion schedules. - All patients or their parents/legal guardians will provide informed consent/assent (as required by law) indicating their awareness of the investigational nature and the risks of this study according to the informed consent process. Exclusion Criteria: - Women who are known to be pregnant or lactating - Patients with significant uncontrolled systemic illness - Serum glutamic oxaloacetic transaminase (SGOT/AST), serum glutamic pyruvate transaminase (SGPT/ALT) > 3 times the upper limit of normal tested within 14 days prior to infusion - Bilirubin > the upper limit of normal tested within 14 days prior to infusion - Patients whose dose of doxorubicin is based on ideal body weight - Patients who weigh < 12 kilograms at time of screening



Primary Contact:

Principal Investigator
Holcombe Grier, MD
Dana Farber Cancer Insitute

Backup Contact:


Location Contact:

Boston, Massachusetts 02115
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.